Altimmune, Inc. Stock News

I am bullish on Altimmune because of their two COVID-19 programs, T-COVID and AdCOVID. Specifically, T-COVID is reminiscent of a Tamiflu, but for COVID-19.

TVB’s 2020 Alt Forward Conference will be unlike any before - this year’s conference will be a fully virtual, multi-dimensional experience, taking pla

Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated v

The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.

Altimmune provides positive updates for AdCOVID. Ovid reports positive Phase 2 ELEKTRA study data.

GAITHERSBURG, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended Jun

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...

GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinica

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and

Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre

GAITHERSBURG, Md., July 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement with Vige

GAITHERSBURG, Md., July 16, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its previously announced underwritten public.

The COVID-19 pandemic has created a gold-rush on vaccine stocks. Many of the small-cap biotech and pharmaceutical companies have experienced 1000%+ gains as investors speculative who will be first.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Altimmune Inc (NASDAQ: ALT...

GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten pub